25 reports

Combination of approved immunotherapies with new in-research immunotherapies has resulted in improved response rates for patients with RCC.

  • Cancer
  • Immunotherapy
  • Renal Cancer
  • Therapy
  • Genentech, Inc.
  • Debio-1143

Subjects were randomized in a ##:##:## ratio to receive no additional treatment, one year of Herceptin treatment or two years of Herceptin treatment.

  • Immunotherapy
  • Therapy
  • Market Size
  • Advaxis, Inc.
  • Genentech, Inc.

Indian Journal of Ophthalmology; ##(##): ## Pfizer.

  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • Clearside Biomedical, Inc.
  • Genentech, Inc.
  • 10.3 ADVAXIS

At the 2012 Society for Immunotherapy Annual Meeting, results from a Phase ## study of CDX-## were presented.

  • Cancer Immunotherapy
  • Immunotherapy
  • Vaccine
  • Advaxis, Inc.
  • Genentech, Inc.

From tool to therapy: a timeline of monoclonal antibody technology.

  • Immunotherapy
  • Medical Biotechnology
  • Monoclonal Antibody
  • AbbVie Inc.
  • Genentech, Inc.

The use of antibody conjugates is growing, including in therapies such as radio immunotherapy and antibody-directed enzyme prodrug therapy.

  • Immunotherapy
  • Therapy
  • United States
  • World
  • Genentech, Inc.

CAMBRIDGE ANTIBODY TECHNOLOGY ##.

  • Immunotherapy
  • North America
  • United States
  • Advaxis, Inc.
  • Genentech, Inc.

VAXIMM will be responsible for conducting two open-label Phase I/ II trials - one in glioblastoma and one in metastatic colorectal cancer.

  • Immunotherapy
  • Therapy
  • Genentech, Inc.
  • Novartis AG
  • Roche Group
  • that is further enhanced in combination with a Listeria-based immunotherapy".
  • at least six months without relapse.

In immununo-oncology one such therapy is E-##, in which AiM is utilizing its expertise in immune cell biology, genomics and small molecules to discover novel precision immunotherapies targeting myeloid lineage cells.

  • Cancer
  • Immunotherapy
  • United States
  • Product Initiative
  • Advaxis, Inc.

Atezolizumab will be the first immunotherapy available for TNBC patients in the firstline setting.

  • Breast Cancer
  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Genentech, Inc.
  • SEP 26, 2016: ADVAXIS' LM TECHNOLOGY IMMUNOTHERAPIES TO BE SHOWCASED IN THREE POSTER PRESENTATIONS AT SITC ANNUAL MEETING
  • MAR 26, 2018: ADVAXIS ANNOUNCES FOUR POSTER PRESENTATIONS HIGHLIGHTING LM-BASED ANTIGEN DELIVERY TECHNOLOGY AT AACR 2018

The paper titled " Anti-PD-## antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy", has been e-published in the Journal for Immunotherapy of Cancer.

  • Cancer
  • Immunotherapy
  • Sexually Transmitted Disease
  • Therapy
  • Advaxis, Inc.
  • Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders
  • 01/29/2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies

Funded by one of the largest Taiwanese pharmaceutical companies, this deal further validates Advaxis' proprietary immunotherapy technology.

  • Cancer
  • Immunotherapy
  • Therapy
  • United States
  • Advaxis, Inc.

Nanda on Immunotherapy in Metastatic TNBC.

  • Breast Cancer
  • Immunotherapy
  • Therapy
  • Advaxis, Inc.
  • Genentech, Inc.
  • MAR 26, 2018: ADVAXIS ANNOUNCES FOUR POSTER PRESENTATIONS HIGHLIGHTING LM-BASED ANTIGEN DELIVERY TECHNOLOGY AT AACR 2018
  • ABION INC

THE PAPER TITLED " ANTI-PD-## ANTIBODY SIGNIFICANTLY INCREASES THERAPEUTIC EFFICACY OF LISTERIA MONOCYTOGENES (LM)-LLO IMMUNOTHERAPY", HAS BEEN E-PUBLISHED IN THE JOURNAL FOR IMMUNOTHERAPY OF CANCER.

  • Immunotherapy
  • Sexually Transmitted Disease
  • Therapy
  • Vaccine
  • Advaxis, Inc.
  • JUL 13, 2017: ADVAXIS LEAD IMMUNOTHERAPY CANDIDATE CONTINUES TO BUILD RECOGNITION AMONG INDUSTRY LEADERS
  • ABION INC

This finding suggests that the combination of Lm-LLO immunotherapy with an anti-PD-## antibody could have clinical application.

  • Cancer
  • Immunotherapy
  • Sexually Transmitted Disease
  • Therapy
  • Advaxis, Inc.

Two patients also received prior immunotherapy.

  • Healthcare
  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • Genentech, Inc.
  • Early-Stage Pipeline Products in Non-Hodgkin's Lymphoma

TERM=RICER& RANK=##.

  • Epidemiology
  • Immunotherapy
  • Lymphoma
  • Therapy
  • Genentech, Inc.

RORg Agonists as a Novel Immunotherapy Approach for Cancer Annual Meeting of the American Association for Cancer Research (AACR); Philadelphia, PA, USA; Apr ## - ##, 2015a: abstract ## and Poster Hu X, Moisan J, Majchrzak K et al.

  • Immunotherapy
  • Pharmaceutical
  • 4SC Discovery GmbH
  • Advinus
  • Genentech, Inc.
  • Human Papilloma Virus (HPV) E7 Protein - Featured News & Press Releases

The paper titled " Anti-PD-## antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy", has been e-published in the Journal for Immunotherapy of Cancer.

  • Immunotherapy
  • Sexually Transmitted Disease
  • Vaccine
  • United States
  • Advaxis, Inc.

GBR ## is based on Glenmark' s innovative BEAT antibody technology platform.

  • Biosimilar
  • Immunotherapy
  • Genentech, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Roche Group

ROCHE - ##/ ## Product ROCHE - ##/ ## ID No.

  • Immunotherapy
  • Medical Biotechnology
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Genentech, Inc.
  • Apr 28, 2015
  • Other Developmental Activities

This finding suggests that the combination of Lm-LLO immunotherapy with an anti-PD-## antibody could have clinical application.

  • Immunotherapy
  • Vaccine
  • United States
  • Company Operations
  • Advaxis, Inc.
  • R&D Progress Research and Development Brief
  • Other Developmental Activities

Bivalent Lm-LLO Immunotherapy demonstrated increased anti-tumor effects when compared to monovalent Lm-LLO immunotherapy in preclinical studies.

  • Immunotherapy
  • Monoclonal Antibody
  • Vaccine
  • World
  • Advaxis, Inc.

" Immunotherapy treatments offer enormous promise in the treatment of lung cancer.

  • Immunotherapy
  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Genentech, Inc.
  • Business Segment Analysis

TALIMOGENE LAHERPAREPVEC IS AN ONCOLYTIC IMMUNOTHERAPY DERIVED FROM HSV-##.

  • Healthcare
  • Immunotherapy
  • Pharmaceutical
  • United States
  • Genentech, Inc.